Aclaris Therapeutics, Inc. (ACRS) PT Set at $50.00 by Cantor Fitzgerald
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) received a $50.00 price target from equities research analysts at Cantor Fitzgerald in a report issued on Wednesday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 83.82% from the company’s previous close.
Other equities research analysts have also recently issued research reports about the company. BidaskClub raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. ValuEngine raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Guggenheim reissued a “buy” rating and set a $40.00 target price on shares of Aclaris Therapeutics in a report on Tuesday, July 4th. Jefferies Group LLC reissued a “buy” rating and set a $36.00 target price on shares of Aclaris Therapeutics in a report on Wednesday, June 28th. Finally, JMP Securities reissued an “outperform” rating and set a $39.00 target price on shares of Aclaris Therapeutics in a report on Friday, September 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $41.25.
Aclaris Therapeutics (ACRS) traded up 1.91% during trading on Wednesday, reaching $27.21. The company had a trading volume of 257,981 shares. The firm’s market capitalization is $727.49 million. The company has a 50-day moving average of $25.83 and a 200-day moving average of $27.20. Aclaris Therapeutics has a 52-week low of $20.15 and a 52-week high of $33.25.
Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $0.12. Analysts expect that Aclaris Therapeutics will post ($3.10) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/05/aclaris-therapeutics-inc-acrs-pt-set-at-50-00-by-cantor-fitzgerald.html.
In related news, Director Andrew N. Schiff purchased 108,601 shares of the company’s stock in a transaction on Wednesday, August 16th. The shares were bought at an average price of $23.02 per share, with a total value of $2,499,995.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 16.30% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of ACRS. FMR LLC increased its holdings in shares of Aclaris Therapeutics by 253.1% in the first quarter. FMR LLC now owns 1,653,937 shares of the biotechnology company’s stock valued at $49,321,000 after buying an additional 1,185,598 shares in the last quarter. Eagle Asset Management Inc. increased its holdings in shares of Aclaris Therapeutics by 287.3% in the second quarter. Eagle Asset Management Inc. now owns 1,357,973 shares of the biotechnology company’s stock valued at $36,828,000 after buying an additional 1,007,343 shares in the last quarter. MARSHALL WACE ASIA Ltd bought a new position in shares of Aclaris Therapeutics in the first quarter valued at $21,116,000. Marshall Wace North America L.P. bought a new position in shares of Aclaris Therapeutics in the first quarter valued at $21,116,000. Finally, Franklin Resources Inc. increased its holdings in shares of Aclaris Therapeutics by 55.4% in the second quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock valued at $53,030,000 after buying an additional 697,104 shares in the last quarter. 95.85% of the stock is currently owned by institutional investors.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.